Evidence map›Paper›PMID 28290049›Full record

ReviewCurrent diabetes reports2017

Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis.

P Wainwright, E Scorletti, C D Byrne

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. OncogeneAmerican journal of cancer research · 2020
    Article
  16. Update in global trends and aetiology of hepatocellular carcinoma.Contemporary oncology (Poznan, Poland) · 2018
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

P WainwrightClinical Biochemistry, University Hospital Southampton, Southampton, UK. patrick.wainwright@uhs.nhs.uk.
E ScorlettiHuman Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
C D ByrneHuman Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
University Hospital Southampton NHS Foundation Trust · GBNIHR Southampton Respiratory Biomedical Research Unit · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to assess the epidemiological evidence for a link between type 2 diabetes and hepatocellular carcinoma and to investigate possible pathophysiological mechanisms. RECENT

findingsThe presence of type 2 diabetes significantly increases the risk of developing hepatocellular carcinoma, and treatment with metformin may be associated with a lower risk. Treatment with insulin and sulphonylureas may be associated with increased risk. The pathophysiology underlying development of hepatocellular carcinoma in this context is complex and is likely to involve increased proinflammatory mediators, oxidative stress, JNK-1 activation, increased IGF-1 activity, altered gut microbiota and immunomodulation. Hepatocellular carcinoma incidence is increasing and this is likely to be linked to the increasing incidence of type 2 diabetes, obesity and the metabolic syndrome. These conditions increase the risk of developing hepatocellular carcinoma, and a greater understanding of the underlying pathophysiology may help with the development of novel treatments.

Indexed as

AnimalsCarcinoma, HepatocellularDiabetes Mellitus, Type 2HumansLiver NeoplasmsMetabolic SyndromeMiceMitogen-Activated Protein Kinase 8ObesityRisk FactorsMitogen-Activated Protein Kinase 8DiabetesHepatocellular carcinomaNon-alcoholic fatty liver diseaseObesityPathogenesisRisk factors

Identifiers

PMID28290049
OpenAlexW2595471827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.